BioInformant - Stem Cell Industry News

TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee | BioInformant Nashville, TN – July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This ...

TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases | BioInformant OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part in...

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases - bioinformant.com/bluerock-the...

Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput | BioInformant New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture Industry-leading throughput enables real-time analysis of up to six micr...

Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput - bioinformant.com/incucyte-cx3...

Longeveron® Announces Licensing of New Cardiac Selective iPSC Technology for Cardiovascular Disease | BioInformant Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Recepto...

Longeveron® Announces Licensing of New Cardiac Selective iPSC Technology for Cardiovascular Disease - bioinformant.com/longeveron-a...

uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development | BioInformant ROCKVILLE, MD, June 16, 2025 – uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC)...

uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development - bioinformant.com/ubrigene-lau...

Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes) | BioInformant July 24, 2025, St. Louis, Missouri — Future Medical Products LLC is pleased to announce the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with ...

Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes) - bioinformant.com/pure-bone-ma...

Induced Pluripotent Stem Cell (iPSC) Industry Trends for 2025 Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprog...

Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...
@riken-brc-en.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social

UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study | BioInformant SHANGHAI, May 23, 2025 — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its prop...

UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study - bioinformant.com/unixell-biot...

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...

Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy... Palo Alto, CA, July 10, 2025 –  Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with ...

Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells - bioinformant.com/vita-therape...

Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes | BioInformant ‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only...

Ciloa has secured €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes - bioinformant.com/ciloa-secure...

REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research -https://bioinformant.com/reprocells-ipsc-seed-stock-clones/

@reprocell.bsky.social

Accelerating Cell And Gene Therapy Development With Excipient GMP Quality Media And Buffers: The Nucleus Biologics Advantage | Nucleus Biologics We are certified to EXCiPACT GMP, EXCiPACT GMP Standard for PAMs, and ISO 9001. Read about the advantages of excipient GMP materials!

Cell & Gene Therapy Developers Need an Excipient-Certified Cell Culture Media Manufacturer -
In cell and gene therapy, product safety and consistency are non-negotiable.

nucleusbiologics.com/blog/acceler...

Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research | BioInformant MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a ne...

Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research - bioinformant.com/hiex-researc...

Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its Exosome Bioproduction Technology | BioInfor... Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as par...

Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its #Exosome Bioproduction Technology - bioinformant.com/everzom-fran...

L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn's Disease | BioInformant HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational Ne...

L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn’s Disease - bioinformant.com/l2-bio-seeks...

LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics | BioInformant LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerg...

LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics - bioinformant.com/lift-bioscie...
@giftoflife.bsky.social

Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development | BioInformant May 20, 2025, MILPITAS, Calif. — Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which ...

Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development - bioinformant.com/applied-stem...

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease | BioInformant Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®,...

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease - bioinformant.com/chu-toulouse...

Altaris Launches Minaris Advanced Therapies, Merging the CDMOs Minaris Regenerative Medicine and WuXi Advanced Therapies | BioInformant Combined Entity will be a Global CDMO Powerhouse in Cell and Gene Therapy In a bold move that has consolidated the landscape of advanced therapy manufacturing, Altaris LLC announced the successful acq...

Altaris Launches Minaris Advanced Therapies, Merging the CDMOs Minaris Regenerative Medicine and WuXi Advanced Therapies - bioinformant.com/altaris-laun...

Pioneering the future of sports with iPS cells FUNROOTS, I Peace, and Reju form a strategic alliance | BioInformant FUNROOTS Co., Ltd. (Tokyo, Japan), I Peace, Inc. (California, USA), and Reju Inc. (Tokyo, Japan) entered a strategic partnership to integrate cutting-edge iPS cell technology into the sports industry,...

Pioneering the future of sports with iPS cells - FUNROOTS, I Peace, and Reju form a strategic alliance - bioinformant.com/funroots-i-p...

Global Exosome-Based Aesthetics (Cosmeceuticals) Market | BioInformant Cosmeceuticals—cosmetic products that deliver pharmaceutical-like benefits—are a rapidly growing sector of the cosmetic and anti-aging industry. Among the most exciting innovations are exosomes, small...

Global Exosome-Based Aesthetics (Cosmeceuticals) Market - bioinformant.com/global-exoso...

Curi Bio and Cook MyoSite Announce Strategic Partnership | BioInformant Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models SEATTLE & PITTSBURGH — Curi Bio, the global leader in human 3D engineered tis...

Curi Bio and Cook MyoSite Announce Strategic Partnership - bioinformant.com/curi-bio-and...

Nikon CeLL Innovation Enters into a Strategic License Agreement with RoosterBio, a US Company, to Enable GCTP/GMP Manufacturing Platform of Human Mesenchymal Stem Cells & Extracellular Vesicle in Japa... TOKYO – Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology co...

Nikon CeLL Innovation Enters into a Strategic License Agreement with RoosterBio, a US Company, to Enable GCTP/GMP Manufacturing Platform of Human Mesenchymal Stem Cells & Extracellular Vesicle in Japan - bioinformant.com/nikon-cell-i...

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing | BioInformant FREDERICK, MD., (April 29, 2025) —RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a ...

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - bioinformant.com/roosterbio-c...
@thermofishersci.bsky.social

Global Demand for CAR-T Cell Therapies by Product in 2025 In recent years, CAR-T therapies have revolutionized the treatment of certain hematological cancers, offering new hope for patients who have exhausted all other options. CAR-T therapies are a form of ...

Global Demand for CAR-T Cell Therapies by Product in 2025 - bioinformant.com/car-t-cell-t...
@novartis.bsky.social

Designer Exosomes: The Future of Targeted Therapy and Regenerative Medicine | BioInformant In the evolving landscape of biomedical innovation, exosomes have emerged as one of the most promising tools for next-generation therapies. These nanoscale, membrane-bound vesicles, naturally secreted...

Designer Exosomes: The Future of Targeted Therapy and Regenerative Medicine - bioinformant.com/designer-exo...

I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S. – Age-Reversed Stem Cell Technology Now Available to the Public – | BioInformant Palo Alto, CA – I Peace, Inc., a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalized iPS cell production and longevity-focused rejuvenat...

I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S. – Age-Reversed Stem Cell Technology Now Available to the Public – bioinformant.com/i-peace-ips-...

Venture Capital Funding Flowing into the iPSC Sector by Year | BioInformant The induced pluripotent stem cell (iPSC) sector has attracted strong venture capital funding in recent years, reflecting growing confidence in its potential across regenerative medicine, drug developm...

Venture Capital Funding Flowing into the iPSC Sector by Year - bioinformant.com/venture-capi...
@kenaitx.bsky.social @aspenneuroscience.bsky.social @axolbio.bsky.social @synthego.bsky.social @evotec.bsky.social

Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next - bioinformant.com/sernova-biot...